Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease Read more
Firm Capital Apartment Real Estate Investment Trust Announces Exchange Approval Of Normal Course Issuer Bid For Debentures Read more